HUP0204159A3 - Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction - Google Patents

Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction

Info

Publication number
HUP0204159A3
HUP0204159A3 HU0204159A HUP0204159A HUP0204159A3 HU P0204159 A3 HUP0204159 A3 HU P0204159A3 HU 0204159 A HU0204159 A HU 0204159A HU P0204159 A HUP0204159 A HU P0204159A HU P0204159 A3 HUP0204159 A3 HU P0204159A3
Authority
HU
Hungary
Prior art keywords
compositions
preparation
erectile dysfunction
prostaglandin
male erectile
Prior art date
Application number
HU0204159A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Nexmed Holdings Inc Robbinsvil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23909154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0204159(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nexmed Holdings Inc Robbinsvil filed Critical Nexmed Holdings Inc Robbinsvil
Publication of HUP0204159A2 publication Critical patent/HUP0204159A2/hu
Publication of HUP0204159A3 publication Critical patent/HUP0204159A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
HU0204159A 2000-01-10 2001-01-10 Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction HUP0204159A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/480,738 US6323241B1 (en) 2000-01-10 2000-01-10 Prostaglandin compositions and methods of treatment for male erectile dysfunction
PCT/US2001/000852 WO2001051053A1 (en) 2000-01-10 2001-01-10 Prostaglandin compositions and methods of treatment for male erectile dysfunction

Publications (2)

Publication Number Publication Date
HUP0204159A2 HUP0204159A2 (hu) 2003-04-28
HUP0204159A3 true HUP0204159A3 (en) 2005-03-29

Family

ID=23909154

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204159A HUP0204159A3 (en) 2000-01-10 2001-01-10 Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction

Country Status (20)

Country Link
US (1) US6323241B1 (enExample)
EP (1) EP1255552B1 (enExample)
JP (2) JP2003519657A (enExample)
KR (1) KR100614361B1 (enExample)
CN (1) CN1394140A (enExample)
AT (1) ATE290383T1 (enExample)
AU (1) AU760576C (enExample)
BE (1) BE2014C001I2 (enExample)
BR (1) BR0107478A (enExample)
CA (1) CA2395217C (enExample)
DE (1) DE60109274T2 (enExample)
ES (1) ES2236245T3 (enExample)
HK (1) HK1047700B (enExample)
HU (1) HUP0204159A3 (enExample)
IL (2) IL150306A0 (enExample)
MX (1) MXPA02006758A (enExample)
PT (1) PT1255552E (enExample)
TR (1) TR200201769T2 (enExample)
WO (1) WO2001051053A1 (enExample)
ZA (1) ZA200205433B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
EA008720B1 (ru) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20090035221A1 (en) * 2002-01-25 2009-02-05 Ramsey Sallis Methods and Compositions for Treatment of Erectile Dysfunction
ATE406900T1 (de) 2002-01-25 2008-09-15 Modular Properties Ltd Verfahren und zusammensetzungen zur behandlung der männlichen erektionsstörung
US20090257956A1 (en) * 2002-01-25 2009-10-15 Ramsey Sallis Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation
AU2003211077A1 (en) * 2002-02-15 2003-09-09 Nexmed (Holdings), Inc. Prostaglandin composition for the treatment of erectile dysfuntion
CN1674912A (zh) * 2002-09-06 2005-09-28 奈克斯麦德控股有限公司 治疗男性勃起障碍的方法
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
EP1605913A2 (en) * 2003-03-21 2005-12-21 Nexmed (Holdings), Inc. Angiogenesis promotion by prostaglandin compositions and methods
AU2004224413A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Prostaglandin compositions for the treatment of erectile dysfunction
AU2004224329B2 (en) 2003-03-21 2009-07-09 Nexmed (Holdings), Inc. Compositions and methods for treatment of premature ejaculation
EP1608378A1 (en) * 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US20050159985A1 (en) * 2003-11-21 2005-07-21 Bertram Carl T. System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US7655659B2 (en) * 2004-08-19 2010-02-02 Applied Genetics Incorporated Dermatics Biomimetic of Evodia rutaecarpa fruit extract for amelioration of inflammation
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
NZ609826A (en) * 2010-12-02 2016-03-31 Nexmed Holdings Inc Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
BR112013025744A2 (pt) 2011-04-07 2016-08-16 Nexmed Holdings Inc composicões para tratamento da doença de raynaud
US10226418B2 (en) 2014-05-12 2019-03-12 Susie Q, Ltd. Arginine-containing topical composition
CN107405346A (zh) 2015-01-20 2017-11-28 Xoc制药股份有限公司 异麦角灵化合物及其用途
BR112017015487A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
EP3266458A1 (en) 2016-07-05 2018-01-10 Fagron B.V. Method and composition and kit for treating erectile dysfunction
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
BE790840A (fr) 1971-11-01 1973-04-30 Upjohn Co Solutions de medicaments instables et leur preparation
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
EP0526566B1 (en) 1990-04-25 1998-11-25 Vivus, Inc. Treatment of erectile dysfunction
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
TR199700930T2 (xx) 1995-03-14 1998-07-21 Vivus Incorporated Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit.
KR20010021625A (ko) * 1997-07-09 2001-03-15 추후보정 개선된 남성발기 기능장애 치료방법 및 그 조성물
AU734734B2 (en) * 1997-10-28 2001-06-21 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6102849A (en) 1999-04-03 2000-08-15 Hakac; John R. Non-surgical penile prosthesis

Also Published As

Publication number Publication date
BR0107478A (pt) 2002-09-03
WO2001051053A1 (en) 2001-07-19
EP1255552A1 (en) 2002-11-13
IL150306A (en) 2007-06-03
ATE290383T1 (de) 2005-03-15
PT1255552E (pt) 2005-06-30
MXPA02006758A (es) 2008-09-12
JP2007302690A (ja) 2007-11-22
CN1394140A (zh) 2003-01-29
CA2395217A1 (en) 2001-07-19
TR200201769T2 (tr) 2002-11-21
AU2934901A (en) 2001-07-24
AU760576B2 (en) 2003-05-15
BE2014C001I2 (enExample) 2020-01-30
DE60109274T2 (de) 2006-02-09
KR100614361B1 (ko) 2006-08-18
CA2395217C (en) 2004-10-26
HUP0204159A2 (hu) 2003-04-28
JP2003519657A (ja) 2003-06-24
DE60109274D1 (de) 2005-04-14
HK1047700A1 (en) 2003-03-07
KR20020073498A (ko) 2002-09-26
EP1255552B1 (en) 2005-03-09
US6323241B1 (en) 2001-11-27
HK1047700B (en) 2005-05-27
ZA200205433B (en) 2003-11-26
IL150306A0 (en) 2002-12-01
AU760576C (en) 2004-04-08
ES2236245T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
HUP0401816A3 (en) Prostaglandin compositions and their use for preparation of medicaments sutable for treatment of male erectile dysfunction
HUP0301892A3 (en) Pharmaceutical compositions for treatment of sexual dysfunction and their preparation
IL153492A0 (en) Treatment of male sexual dysfunction
HUP0400281A3 (en) Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
HUP0301336A3 (en) Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions
AU6118001A (en) Combination therapeutic compositions and methods of use
PL366430A1 (en) Sustained release formulations of oxymorphone
HUP0101543A3 (en) Pharmaceutical compositions for treating femal sexual dysfunction
PL355844A1 (en) Novel pharmaceutical compositions of anti-tubrcular drugs and process for their preparation
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
AU9092501A (en) Compositions and methods for inhibition of hiv-1 infection
EP1252325A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 INFECTION
HUP0400548A3 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
IL151314A0 (en) Micelles, methods for their preparation and methods for delivery of micelles to patients
ZA200410009B (en) Compositions and methods for ameliorating of human female sexual dysfunction
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0300860A3 (en) Pharmaceutical compositions suitable for treatment of urinary dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
HUP0303055A3 (en) Polymorphs of zaleplon and methods for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished
NF4A Restoration of patent protection
GB9A Succession in title

Owner name: FERRING INTERNATIONAL CENTER S.A., CH

Free format text: FORMER OWNER(S): NEXMED HOLDINGS, INC., US